Nuo Therapeutics, Inc. (AURX)

Market Cap	58.60M -28.8%
Revenue (ttm)	5.20M +166.6%
Net Income	-2.01M
EPS	-0.04
Shares Out	48.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	1.190
Previous Close	1.210
Day's Range	1.190 - 1.190
52-Week Range	0.770 - 3.230
Beta	-800.11
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Nuo Therapeutics

Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 10
• Stock Exchange: OTCMKTS
• Ticker Symbol: AURX

Financial Performance

In 2025, Nuo Therapeutics's revenue was $3.31 million, an increase of 142.72% compared to the previous year's $1.37 million. Losses were -$2.51 million, 8.11% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 8, 2026

Data Sources Report a data error